ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Javier Pascual, Gerhardt Attard, François‐Clément Bidard et al. · Annals of Oncology · 2022
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society for Medical Oncology convened an expert working group to review the analytical and clinical validity and utility of ctDNA assays. For patients with advanced cancer, validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, and may be used in routine clinical practice, provided the limitations of the assays are taken into account. Tissue-based testing remains the preferred test for many cancer patients, due to limitations of ctDNA assays detecting fusion events and copy number changes, although ctDNA assays may be routinely used when faster results will be clinically important, or when tissue biopsies are not possible or inappropriate. Reflex tumour testing should be considered following a non-informative ctDNA result, due to false-negative results with ctDNA testing. In patients treated for early-stage cancers, detection of molecular residual disease or molecular relapse, has high evidence of clinical validity in anticipating future relapse in many cancers. Molecular residual disease/molecular relapse detection cannot be recommended in routine clinical practice, as currently there is no evidence for clinical utility in directing treatment. Additional potential applications of ctDNA assays, under research development and not recommended for routine practice, include identifying patients not responding to therapy with early dynamic changes in ctDNA levels, monitoring therapy for the development of resistance mutations before clinical progression, and in screening asymptomatic people for cancer. Recommendations for reporting of results, future development of ctDNA assays and future clinical research are made.
Cited by 753 works. doi:10.1016/j.annonc.2022.05.520
Authors
- Javier Pascual
- Gerhardt Attard
- François‐Clément Bidard
- Giuseppe Curigliano
- Leticia De Mattos‐Arruda
- Maximilian Diehn
- Antoîne Italiano
- Johan Lindberg
- Jason D. Merker
- Clara O. Montagut
- Nicola Normanno
- Klaus Pantel
- George E. Pentheroudakis
- Sanjay Popat
- Jorge Sergio Reis-Filho
- Jeanne Tie
- Joan Seoane
- N. Tarazona
- Takayuki Yoshino
- Nicholas C. Turner
References
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- Circulating mutant DNA to assess tumor dynamics
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- Integrative Clinical Genomics of Advanced Prostate Cancer
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer